File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)

Article: Prevention of Dabigatran-related Gastrointestinal Bleeding With Gastroprotective Agents: A Population-Based Study

TitlePrevention of Dabigatran-related Gastrointestinal Bleeding With Gastroprotective Agents: A Population-Based Study
Authors
Issue Date2015
Citation
Gastroenterology, 2015 How to Cite?
AbstractBACKGROUND & AIMS: Use of dabigatran, an inhibitor of thrombin, increases risk of gastrointestinal bleeding (GIB). However, it is not clear whether gastroprotective agents (GPAs) prevent GIB in dabigatran users. We investigated the risk of GIB and the role of GPAs (including proton-pump inhibitors and histamine type-2 receptor antagonists) in patients using dabigatran. METHODS: We performed a retrospective cohort study using a population-wide database managed by the Hong Kong Hospital Authority. Patients newly prescribed dabigatran from 2010 through 2013 were included in the analysis. Poisson regression was used to assess the risk of GIB in dabigatran users by incidence rate ratio (IRR), adjusted for patient characteristics, comorbidities, and concurrent medications. RESULTS: Among the 5041 patients newly prescribed dabigatran, 124 (2.5%) developed GIB during follow-up (4.2/100 patient-years). The risk of GIB in this population increased among patients 75 y old or older (IRR, 2.47; 95% confidence interval [CI], 1.66-3.68), patients with a history of peptic ulcers or GIB (IRR, 2.31; 95% CI, 1.54-3.46), and patients who used aspirin (IRR, 1.52; 95% CI, 1.03-2.24). Concomitant use of GPAs was associated with a reduced risk of GIB (IRR, 0.52; 95% CI, 0.35-0.77). Subcategory analysis showed that use of proton-pump inhibitors (IRR, 0.53; 95% CI, 0.31-0.91) or histamine type-2 receptor antagonists (IRR, 0.61; 95% CI, 0.40-0.94) were associated with lower risk of GIB. Further analysis revealed that the risk reduction by GPAs was significant for only upper GIB (IRR, 0.29; 95% CI, 0.15-0.54) and only for patients with prior history of peptic ulcers or GIB (IRR, 0.14; 95% CI, 0.06-0.30). CONCLUSIONS: In the Hong Kong population, use of GPAs and was associated with a reduced risk of GIB in patients taking dabigatran. The association was stronger for upper GIB than lower GIB, and in patients with prior history of peptic ulcers or GIB.
Persistent Identifierhttp://hdl.handle.net/10722/211827

 

DC FieldValueLanguage
dc.contributor.authorChan, EW-
dc.contributor.authorLau, CY-
dc.contributor.authorLeung, WK-
dc.contributor.authorMok, MTC-
dc.contributor.authorHe, Y-
dc.contributor.authorTong, SM-
dc.contributor.authorWong, ICK-
dc.date.accessioned2015-07-21T02:12:14Z-
dc.date.available2015-07-21T02:12:14Z-
dc.date.issued2015-
dc.identifier.citationGastroenterology, 2015-
dc.identifier.urihttp://hdl.handle.net/10722/211827-
dc.description.abstractBACKGROUND & AIMS: Use of dabigatran, an inhibitor of thrombin, increases risk of gastrointestinal bleeding (GIB). However, it is not clear whether gastroprotective agents (GPAs) prevent GIB in dabigatran users. We investigated the risk of GIB and the role of GPAs (including proton-pump inhibitors and histamine type-2 receptor antagonists) in patients using dabigatran. METHODS: We performed a retrospective cohort study using a population-wide database managed by the Hong Kong Hospital Authority. Patients newly prescribed dabigatran from 2010 through 2013 were included in the analysis. Poisson regression was used to assess the risk of GIB in dabigatran users by incidence rate ratio (IRR), adjusted for patient characteristics, comorbidities, and concurrent medications. RESULTS: Among the 5041 patients newly prescribed dabigatran, 124 (2.5%) developed GIB during follow-up (4.2/100 patient-years). The risk of GIB in this population increased among patients 75 y old or older (IRR, 2.47; 95% confidence interval [CI], 1.66-3.68), patients with a history of peptic ulcers or GIB (IRR, 2.31; 95% CI, 1.54-3.46), and patients who used aspirin (IRR, 1.52; 95% CI, 1.03-2.24). Concomitant use of GPAs was associated with a reduced risk of GIB (IRR, 0.52; 95% CI, 0.35-0.77). Subcategory analysis showed that use of proton-pump inhibitors (IRR, 0.53; 95% CI, 0.31-0.91) or histamine type-2 receptor antagonists (IRR, 0.61; 95% CI, 0.40-0.94) were associated with lower risk of GIB. Further analysis revealed that the risk reduction by GPAs was significant for only upper GIB (IRR, 0.29; 95% CI, 0.15-0.54) and only for patients with prior history of peptic ulcers or GIB (IRR, 0.14; 95% CI, 0.06-0.30). CONCLUSIONS: In the Hong Kong population, use of GPAs and was associated with a reduced risk of GIB in patients taking dabigatran. The association was stronger for upper GIB than lower GIB, and in patients with prior history of peptic ulcers or GIB.-
dc.languageeng-
dc.relation.ispartofGastroenterology-
dc.titlePrevention of Dabigatran-related Gastrointestinal Bleeding With Gastroprotective Agents: A Population-Based Study-
dc.typeArticle-
dc.identifier.emailChan, EW: ewchan@hku.hk-
dc.identifier.emailLeung, WK: waikleung@hku.hk-
dc.identifier.emailTong, SM: tongsma@hkucc.hku.hk-
dc.identifier.emailWong, ICK: wongick@hku.hk-
dc.identifier.authorityChan, EW=rp01587-
dc.identifier.authorityLeung, WK=rp01479-
dc.identifier.authorityWong, ICK=rp01480-
dc.identifier.doi10.1053/j.gastro.2015.05.002-
dc.identifier.hkuros245418-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats